STAAR Surgical Generates $464,000 in Cash from Operations During Thi...(t of Operations 2008 A/C Chgs...),Health

Date:11/2/2009

t of Operations 2008 A/C Chgs A/C Chgs Sales ---- -------- -------- ----- Net sales $56,737 $- $56,737 100% Cost of sales 26,990 (1,500) 25,490 45% ------ ------ ------ Gross profit 29,747 1,500 31,247 55% ------ ----- ------ Selling, general and administrative expenses: General and administrative 11,441 - 11,441 20% Marketing and selling 20,627 - 20,627 36% Research and development 5,965 - 5,965 11% Loss on settlement of pre- existing distribution arrangement 3,850 (3,850) - 0% ----- ------ -- Total selling, general and administrative expenses: 41,883 (3,850) 38,033 67% ------ ------ ------ Operating loss (12,136) 5,350 (6,786) -12% ------- ----- ------ Other income (expense): 0% Interest income 138 - 138 0% Interest expense (645) - (645) -1% Gain on foreign currency (329) - (329) -1% Other income, net 130 - 130 0% -- --- Total other (expense) income, net (706) - (706) -1% ---- -- ---- Loss
'/>"/>

SOURCE STAAR Surgical Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Related medicine technology :

1. STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York
2. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
5. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
6. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
7. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
8. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
9. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
10. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
11. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery